A Human Cell Models Company

The DBM Difference

Leveraging Diseased and Normal Human Cell Models

The DBM Difference

Our 3D polycystic kidney disease (PKD) model system and multiplexed bioassays have proven pathophysiological relevance in predicting effective therapeutic targets, pathways, and potent, effective lead compounds.

See How It Works

Our Human Taste Bud Tissue-Derived Cell Models are Excellent Predictors of Bitter, Sweet, or Salty Taste

Learn More

Our Methods and Approaches are Relevant to Any Normal or Diseased Human Cell

Learn More
Quality Communication IconQuality Communication
Exceptional Service IconExceptional Service
Customization IconCustomization

DBM is a human cell models life sciences and biotechnology company founded in 2007. Our underlying principle is that if the end goal is to discover and use drugs for human patients, it makes the most sense to integrate the most relevant human cell platforms as early as possible into the drug discovery and validation process. We apply this principle to all our CRO and R&D projects.

Leveraging Human Cell Platform Technologies

DBM's mission is to fill a critical niche within the modern drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery.

Learn More

News & Publications

DiscoveryBioMed, Inc., A Human Cell Models Company, Is Adding Additional Human Tissue and Cell Sectors Driven by Industry Client and Collaborator Demand

2021 was an unprecedented revenue generation year. We were humbled and honored to serve or support over 50 industry clients worldwide. Driven by client demand, we are deepening our efforts…

Learn More

2021-2022 Focus – Utility of DBM’s Diseased and Normal Human Cell Platforms and Bioassays in Metabolomics, Genomics, Proteomics and Medium-throughput Screening

DiscoveryBioMed, Inc. has matured into a premier Human Cell Models CRO by growing, expanding and leveraging its diseased and normal human cell cultures, platforms and bioassays into almost every human…

Learn More

2021-2022 Focus – Validation of the Output of Artificial Intelligence-driven Drug Discovery Initiatives with DBM’s Diseased and Normal Human Cell Platforms and Bioassays

As a premier Human Cell Models CRO, a growing sector for DiscoveryBioMed, Inc. is validation of drug targets and drug candidates identified by artificial intelligence (AI)-based inquiry. AI can identify…

Learn More

We are very positive on your customized and collaborative approach to CRO services projects. Your communication skills are excellent and we can tell that you work on that consistently. These factors helped us to decide to work with you on a long-term project.

Principal from a small Biotechnology company

The human taste bud cell cultures that you are developing and the bioassays that you have developed, along with the growth formats that you are implementing, could be game changers in a vigorous industry involving foods, beverages, food additives, food ingredients and the like.

Consultant familiar with the taste industry

Your company is one of a few if not the only Renal CROs globally and we have been searching for them vigorously recently.

Principal from a large BioPharmaceutical company client

Your 3D ADPKD cystogenesis assays are the most developed and are superior to other laboratories attempting to do the same profiling assays.

Principal from a small Biotechnology company

Your genotyped primary human ADPKD cells have been vitally important for our genomics studies in ADPKD.

Principal from a genomics unit within a large BioPharmaceutical company client

The biomarker data derived from your primary human ADPKD cell cultures from multiple donors matched our data derived from whole PKD kidney tissue.

Principal from a medium-sized Biotechnology company client